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Abstract 
Inflammatory bowel disease collectively known as Crohn’s disease and ulcerative colitis are 
chronic inflammatory diseases of the digestive tract. Periods of active and inactive disease are 
common along the trajectory of this illness. A range of symptoms such as fatigue, diarrhoea and 
abdominal pain are experienced and are often very debilitating in nature resulting in significance 
interference in daily life. Despite this, to date research in the area of symptoms remains an under-
explored topic. This paper aims to discuss current approaches to symptom assessment in IBD and 
the potential to measure symptom burden in further research, in order to gain a greater 
understanding into the experiences of individuals with IBD. 
Keywords: Crohn’s disease; Inflammatory Bowel Disease; Symptoms; Symptom assessment; 
Ulcerative colitis; 
Introduction 
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the digestive tract. 
The two major types of IBD are Crohn’s disease and ulcerative colitis. Both of these chronic illnesses 
are characterised by periods of active and inactive disease. Cardinal symptoms of IBD include 
diarrhoea, abdominal pain, weight loss, bloody diarrhoea and faecal urgency, which are considerably 
more intense during periods of relapsing disease. However it is now known that individuals with IBD 
also experience irritable bowel syndrome (IBS)-type symptoms during periods of apparent inactive 
disease. 
1 2 3
 These symptoms can result in interference in daily life and potentially impose significant 
symptom burden. Recent published guidelines on the management of IBD in adults primarily used by 
clinicians in the United Kingdom 
4
 revealed symptoms of pain and fatigue as an under-researched 
area of IBD. Further investigation into the understanding of the cause and impact of symptoms 
particularly during inactive disease states are recommended. In this paper, current approaches to 
symptom assessment in individuals with IBD are examined including the potential to measure 
symptom burden in research. The need for a more comprehensive measure that incorporates a wide 
range of self-reported symptoms from a multidimensional perspective of symptom burden is 
highlighted.  
Current Approaches to Symptom Assessment in IBD 
Research to date indicates that there is a high prevalence of symptoms among patients with 
Crohn’s disease or ulcerative colitis, with some symptoms more prevalent than others. A number of 
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epidemiological studies 
5 6
 have found that the occurrence of symptoms experienced by individuals 
with IBD is high, although variable. These epidemiological studies are however limited due to the 
small number of symptoms (n = 8) assessed and typically include only the physical cardinal 
symptoms of IBD. Research now indicates that individuals with IBD also experience IBS-type 
symptoms such as abdominal distension, mucus, pain relieved with bowel movements, change in 
frequency of bowel movement, change in the consistency of bowel movement, straining, incomplete 
evacuation, bowel urgency and constipation. A study by Zaman et al. 
7
 found that the occurrence of 
these symptoms was reported by over 40% of patients with IBD. Likewise, studies by Keohane et al. 
1
 
and Minderhoud et al. 
3 
who sampled only patients defined as being in clinical remission found a 
similar high occurrence of IBS-type symptoms. The prevalence rates of IBS-type symptoms have 
been found to be three times higher in patients with ulcerative colitis in remission compared to 
controls. 
2
 In addition, Ansari et al. 
2
 reported similar levels of impaired health-related quality of life 
in individuals with ulcerative colitis in active and inactive disease states. This evidence suggests that 
patients with IBD in remission experience potentially significant symptoms which may be overlooked 
in clinical practice. According to Keohane et al. 
1
, “Clinicians are frequently challenged to interpret 
gastrointestinal symptoms in patients with inflammatory bowel disease, who…appear to be in 
remission” (p. 1). Long and Drossman 
8
 differentiate between disease (pathological state) and illness 
(subjective experiences of patients) suggesting that patients’ experiences of illness may vary 
considerably in relation to their disease status. A review by McColl 
9
 highlighted a lack of 
concordance between healthcare professionals and patients on symptom reporting. Objective 
assessments of symptoms are not recognised as the most appropriate approach, due to an 
underestimation of symptoms by clinicians. McColl 
9
 concluded that symptom assessment from the 
patient’s perspective is now recommended best practice, which coincides with recent emphasis on 
patient-reported outcomes.  
To date the focus of symptom assessment in IBD has been predominantly on symptom 
severity or disease activity in terms of remission and relapse. Research on ‘disease activity’ in IBD 
has been conducted for many years, with a variety of clinical disease activity indices available for 
assessment of patients with IBD, most of which are disease specific for either Crohn’s disease (e.g. 
Crohn’s Disease Activity Index, Harvey-Bradshaw Index) or ulcerative colitis (e.g. Powell Tuck Index, 
Ulcerative Colitis Disease Activity Index, Simple Clinical Colitis Activity Index). However, previous 
research on the assessment of disease activity with existing indices has provided little information 
about symptom severity experiences from patients with IBD because most indices are designed to 
provide a global severity score representative of remission or relapse of the disease. 
10 11
 In addition, 
the limited number of symptoms assessed may not adequately capture the range of symptoms that 
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patients with IBD may experience. A key criticism of the Crohn’s Disease Activity Index, which is 
considered the gold standard for measuring disease activity in Crohn’s disease, is that it fails to 
include a subjective assessment of systemic features, such as fatigue into its composition.
12
 
Furthermore, disease activity indices are completed from the physicians perspective based on 
clinical and laboratory variables. Therefore, current symptom measures appear inadequate as 
measures for identifying the most problematic symptoms experienced by individuals with IBD. 
Perhaps a multidimensional measure of symptom burden may be more suitable at providing richer 
information on the symptom experiences of individuals with IBD. 
13
 
Symptom Burden Measurement: Implications for IBD 
Symptom burden is a distinct measure of the experience of symptoms that incoporates the 
physiological and psychological functioning of the individual experiencing the symptoms. The 
concept is most commonly referred to in the oncology literature, in particular in the medical and 
psychology literature. However, recently a growing body of literature on symptom burden is 
apparent in the nursing literature and in the area of chronic illnesses. In 2007, Gapstur 
14
 conducted 
a concept analysis of symptom burden and identified five key attributes of symptom burden, namely 
dynamic, multidimensional, quantifiable, subjective and physiological burden. Symptom burden is a 
subjective, dynamic concept in that it is the patient’s own perception of a constantly evolving 
experience. Gapstur 
14
 refer to symptom burden as composing of multiple dimensions including the 
prevalence, severity and frequency of symptoms. These multiple dimensions are quantifiable or 
measureable in nature. Gapstur highlighted some inconsistency among researchers in terms of what 
dimensions of concept of symptom burden have been studied ranging from a measure of the 
number of symptoms (prevalence) experienced by individuals to measuring severity and/or 
frequency. Although Gapstur 
14
 identified symptom distress as a related concept to symptom 
burden, previous researchers have measured distress as a dimension of symptom burden 
15 16
, thus 
highlighting some ambuity surrounding the measurement of the concept.  
Studies on symptom burden were reviewed across a range of chronic illnesses, namely, 
oncology, cardiac, respiratory and renal. Variation in approaches to measuring symptom burden is 
evident in terms of assessment methodologies. There is a range of instruments used across studies 
to investigate symptom burden which vary in the number of dimensions measured. Conceptual or 
theoretical perspectives on symptom burden are not explicitly evident among studies, however 
studies that measured symptom burden using the Memorial Symptom Assessment Scale (MSAS) 
originally developed by Portenoy et al. 
17
 for cancer patients reflect current conceptual 
understandings of symptom burden as being multidimensional. 
14 16
 Studies that have used the MSAS 
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measured symptom burden in terms of severity, distress and frequency. Instruments used in other 
studies such as the Edmonton Symptom Assessment System (ESAS), modified ESAS, and Dialysis 
Symptom Indx (DSI) measured fewer dimensions than the MSAS. Likewise, the MD. Anderson 
Symptom Inventory, which is most commonly used in oncology populations, have assessed the 
severity of symptoms only but also incorporates item on inferences with daily living. Contrary to 
Gapstur’s 
14
 conceptualisation which includes symptom prevalence as a quantifiable dimension of 
symptom burden, prevalence has not been measured as a dimension of symptom burden in chronic 
illnesses studies, apart from epidemiological studies investigating the burden of disease in 
populations. Prevalence data are frequently presented and provide useful information on symptoms 
commonly experienced by individuals with similar chronic illnesses, and the mean number of 
symptoms that individuals can experience. However, prevalence data do not contribute to a 
measure of symptom burden. Furthermore, some disparity is evident among the type of symptoms 
assessed in studies investigating symptom burden, with physical symptoms assessed mostly or 
exclusively compared to few or no psychological symptoms assessed. It is known that individuals 
with various chronic illnesses are burdened by psychological symptoms 
18
, therefore highlighting the 
importance of including psychological symptoms in the measurement of symptom burden.  
It can be gleaned from studies on chronic illness that the quantifiable dimensions of 
symptom burden are severity, frequency and distress. From existing measures of symptom burden 
used in previous research studies, the Memorial Symptom Assessment Scale appears to have the 
greatest potential as it includes each of these salient dimensions (namely, severity, frequency and 
distress) and a broad range of both physical and psychological symptoms. However, this research 
instrument has not been previously used in the IBD population. Considering the instrument was 
originally developed in an oncology population, there is a need to modify the instrument by adding 
supplementary IBD specific symptoms. Some symptoms in the original MSAS, for example hair loss, 
are inappropriate in assessing symptom burden in IBD, whereas other symptoms such as rectal bleed 
are cardinal to the condition. The MSAS has been previously deemed a reliable and valid scale. 
17 19 20 
21 22
 In addition, it has been modified to be disease-specific in a number of population groups such as 
cystic fibrosis and heart failure. 
19 20
 Therefore, following further development of the MSAS specific 
for the assessment of symptom burden in IBD, there is a need to assess the psychometric properties 
of the revised instrument. Given the growing body of evidence that individuals living with chronic 
illnesses are burdened by symptoms and the recent call for more research into the area of 
symptoms in IBD 
4
, it is now timely and desirable to investigate the level of symptom burden 
experienced by individuals with IBD. Currently, the researcher is conducting a mixed methods study 
investigating this topic used a modified version of the MSAS to investigate the level of symptom 
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burden experienced in a sample of individuals with Crohn’s disease and ulcerative colitis of varying 
disease activity. 
Conclusion 
In conclusion, symptoms are a complex phenomenon and are recognised as having adverse 
effects on individuals’ lives. Symptoms are known to be problematic among individuals diagnosed 
with IBD, yet they remain an unresearched topic. There is a need for a new direction in the 
measurement of symptoms in future IBD research, such as the newly evolving measurement of 
symptom burden. To date, symptom burden is a forgetten area of measurement in IBD, compared to 
the growing body of literature in the area of other chronic illnesses. This multidimensional 
assessment of symptoms would provide a deeper understanding into the symptom burden 
experiences of individuals with IBD along their relapsing and remitting disease trajectory. In turn, 
this data may contribute to the development of new intervention strategies aimed at lowering the 
level of symptom burden experienced by individuals with IBD and thus improve quality of life.   
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